Bayer to offer access to its owned glyphosate studies
Monheim, November 21, 2018 – Bayer will soon include safety study summaries of glyphosate on its dedicated transparency platform. This next step will mark the first anniversary of the company’s Transparency Initiative, having been launched on 7 December 2017.
“Our commitment to transparency remains core to our mission as we move forward as a combined company,” said Liam Condon, Member of the Board of Management of Bayer AG and President of the Crop Science Division. “We recognize that people around the world want more information around glyphosate – and we are eager to offer access to our glyphosate-related safety data on our dedicated transparency platform. This platform has set new standards of accountability and responsibility in the sector; we pledge to use it as a springboard to continue to share science-based information with the public.”
Bayer’s platform demonstrates how transparency around crop protection safety studies can help the company achieve its commitment to sound science and the safe use of its products, while at the same time maintaining confidential business information. This initiative has recently been recognized as “Best Public Outreach Program” at the 2018 Agrow Awards for delivering excellence in the communication of information on the benefits of agrochemical or agbiotech products.
In addition to the glyphosate study summaries which will be made available on December 7, 2018 access to the underlying safety study reports – owned by Bayer and submitted for the review that led to the European substance renewal decision in December – will be enabled next year.
Bayer is a global enterprise with core competencies in the life science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of 35.0 billion euros. Capital expenditures amounted to 2.4 billion euros, R&D expenses to 4.5 billion euros. For more information, go to www.bayer.com.
Utz Klages, phone +49 2173 38 3125
Find more information at www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.